Gene therapy for lung cancer: Practice and promise

Annali Italiani di Chirurgia

Volumn 75, Issue 3, 2004, Pages 279-289

  Vattemi, E ^a   Claudio, P P ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Gene therapy; Lung cancer

Indexed keywords

APOPTOSIS; CLINICAL TRIAL; COMPARATIVE STUDY; EDITORIAL; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; IMMUNOTHERAPY; LUNG TUMOR; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PROTO ONCOGENE; RESEARCH; SUICIDE TRANSGENE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENES, TRANSGENIC, SUICIDE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENES; RESEARCH;

EID: 16644381856     PISSN: 0003469X     EISSN: 2239253X     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Williams M.D., Sandler A.B.: The epidemiology of lung cancer. Cancer Treat Res, 2001, 105:31-52.
2. Jenkins R.G., McAnulty R.J., Hart S.L., Laurent G.J.: Pulmonary gene therapy. Realistic hope for the future, or false dawn in the promised land Monaldi Arch Chest Dis, 2003 Jan-Mar, 59(1):17-24.
3. Quinlan D.C., Davidson A.G., Summers C.L., et al: Accumulation of p. 53 protein correlates with a poor prognosis in human lung cancer. Cancer Res, 1992, 52:4828-4831.
4. Nishio M., Koshikawa T., Kuroishi T., et al: Prognostic significance of abnormal p. 53 accumulation in primary, resected non-small- cell lung cancers. J Clin Oncol, 1996, 14:497-502.
5. Ohsaki Y., Toyshima E., Fujiuchi S., et al: bcl- and p. 53 protein expression in non-small cell lung cancers: Correlation with survival time. Clin Cancer Res, 1996, 2:915-920.
6. Levine A.J.: P. 53, the cellular gatekeeper for growth and division. Cell, 1997, 88:323-331.
7. Lowe S.W., Ruley H.E., Jacks T., et al: P. 53-dependent apop- tosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74:957-967.
8. Salgia R., Skarin A.T.: Molecular abnormalities in lung cancer. J Clin Oncol, 1998, 16:1207-1217.
9. Claudio P.P., Howard CM., Baldi A., De Luca A., Fu Y Condorelli G., Sun Y., Colbum N., Calabretta B., Giordano A.: p!30/pRb2 has growth suppressive properties similar to yet distintive from those of retinoblastoma family members pRb and p. 107. Cancer Res, 1994, 54:5556-5560.
10. Russo G, Claudio P.P., Fu Y Stiegler P., Yu Z Macaluso M., Giordano A.: pRB2/pl30 target genes in non-small lung cancer celb identified by microarray analysis. Oncogene, 2003 Oct, 9, 22(44):6959-69.
11. Okamoto A., Ilussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., Demetrick D.J., Serrano M Hannon G.J., Shiseki M., Zariwala M., Mong Y., Beach D.H., Yokota J., Harris C.C.: Mutations in the pl6INK4/MTS ', CDKN2, pl5'NK4B, MTS2, and p. 18 genes in primary and metastatic lung cancer. Cancer Res, 1995, 55:1448- 1451.
12. Otterson G.A., Khleif S. N, Chen W, Coxon A.B., Kaye F.J.: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of pl6INK4 protein induction by 5aza2'deoxycytidine. Oncogene, 1995, 11:1211-1216.
13. Gazzeri S., Gouyer V., Vour'ch C, Brambilla C, Brambilla E.: Mechanisms ofpl6°DKN2/MTS1 inactivation in non small-cell lung cancers. Oncogene, 1998, 16:497-504.
14. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R, Saccomanno G., Gabrielson E., Baylin S.B., Herman J.G.: Aberrant methylation of pl6(Ink4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA, 1998, 95:11891-11896.
15. Lee J.H., Lee C.T., Yoo C.G., Hong Y.K., Kim C.M., Han S.K., Shim Y.S., Carbone D.P., Kim Y.W.: The inhibitory effect of adenovirus-mediated pl6INK4a gene transfer on the proliferation of lung cancer cell line. Anticancer Res, 1998, 18:3257-3261.
16. Bos J.L.: Ras oncogene in human cancer: A review. Cancer Res, 1989, 49:4682-4689.
17. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J, Meijer C.J., Wagenaar S.S., Vanderschueren R.G., van Zandwijk N., Mooi W.J., et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med, 1990 Aug, 30, 323(9):561-5.
18. Rodenhuis S., Slebos R.J.: The ras oncogenes in human lung cancer. Am Rev Respir Dis, 1990 Dec, 142(6 Pt 2):27-30.
19. Richardson G.E., Johnson B.E.: The biology of lung cancer. Semin Onco, 1993, 2:105.
20. Sobol R.E., Astarita R.W., Hofeditz C., et al: Epidermal growth factor receptor expression in human lung carcinomas definited by a monoclonal antibody. J. Natl cancer Inst, 79:403-405.
21. Berger M.S., Gullick W.J., Greenfield C., et al: Epidermal growth factor receptors in lung tumours. J Pathol, 1987, 152:297-307.
22. Rusch V., Baselga J., Cordon-Cardo C., et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancer and adjacent benign lung. Cancer Res, 1993, 53:2379-2385.
23. Hirsch F.R., Varella-Garcia M., Franklin W.A., et al: Evaluation of HER2/neu in non-small cell lung cancer by iinmunohistochemistry and fluorescence in-situ hybridization (FISH) techniques. Br J Cancer, 2002, 86: 1449-1456.
24. Plisaki Y., Tanno SM, Fujita Y., et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p. 53 overexpression. Oncol Rep, 2000, 7:603- 607.
25. Rusch V., Klinistra D, Venkatraman E., et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in respectable non-small celllung cancer but does not predict tumor progression. Clin Cancer Res, 1997, 3:515-522.
26. O'Byme K.J, Goddard J., Giatromanolaki A., Koukourakis M.I.: Vascular endothelial growth factor expression in non-small cell lung cancer. Methods Mol Med, 2003, 74: 357-73.
27. Fontanini G., Faviana P., Lucchi M, Boldrini L., Mussi A., Camacci T., Mariani M.A., Angeletti C.A., Basolo F., Pingitore R.: A high vascular count and overexpression of vascular-endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer, 2002 Feb, 12, 86(4):558-63.
28. Koukourakis M.I., Giatromanolaki A., Thorpe P.E., Brekken R.A., Sivridis E, Kakolyris S., Georgoulias V., Gatter K.C., Harris A.L.: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res, 2000 Jun 1, 60(11): 3088-95.
29. Pezzella F, Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., Mason D.Y.: hcl-2 protein in non-small-cell lung carcinoma. N Engl J Med, 1993 Sep 2, 329(10):690-4.
30. Kaiser U., Schilli M, Haag U., Neumann K., Kreipe H, Kogan E., Havemann K.: Expression of hcl-2-protein in small cell lung cancer. Lung Cancer. 1996 Aug, 15(1):31-40.
31. Cristiano R.J., Xu B., Nguyen D., Schumacher G., Kataoka M, Spitz F.R., Roth J.A.: Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detect Prev, 1998, 22:445-454.
32. Kay M.A., Glorioso J.C., Nadini L.: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med, 2001, 7:33.
33. Gilboa E.: Retroviral gene transfer: applications to human therapy. Prog Clin Biol Res, 1990, 352:301-311.
34. Miller A.D.: Retrovirus packaging cells. Hum Gene Ther, 1990, 1:5-14.
35. Comatta K., Morgan R.A., Anderson W.F.: Safety issues related to retroviral-mediated gene transfer in humans. Hum Gen Ther, 1991, 2:5.
36. Stewart P.L., Burnett R.M., Cyrklaff M., Fuller S.D.: Image reconstruction reveals the complex molecular organization of adenovirus. Cell, 1991, 67:145-154.
37. Stratford-Perricaudet L.D., Levrero M., Chasse J.F., Perricaudet M., Briand P.: Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther, 1990, 1:241-256.
38. Yang Y, Li Q, ErtI H.C., Wilson J.M.: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol, 1995 Apr, 69(4):2004-15.
39. Podsakoff G, Wong K.K. Jr., Chatterjee S.: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol, 1994, 68:5656-5666.
40. Kotin R.M., Siniscalco M, Samulski R.J., Zhu X.D., Hunter L, Laughlin C.A., McLaughlin S., Muzyczka N., Rocchi M, Bems K.I.: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA, 1990, 87:2211-2215.
41. Otake K., Ennist D.L., Harrod K., Trapnell B.C.: Hum Gene Ther. Non specific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. 1998 Oct 10, 9(15):2207-22.
42. Glorioso J.C., De Luca N.A., Fink D.J.: Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol, 1995, 49:675-710.
43. Bennett C.F., Chiang M.Y., Chan H., Shoemaker J.E., Mirabelli C.K.: Cationic lipids enhance cellular uptake and activity of pho- sphorothioate antisense oligonucleotides. Mol Pharmacol, 1992, 41:1023-1033.
44. Cullis P.R., Chonn A.: Recent advances in liposome technologies and their applications for systemic gene delivery. Adv Drug Deliv Rev, 1998 Mar, 2;30(1-3):73-83.
45. Stribling R, Brunette E., Liggit D, Gaensler K., Debs R.: Aerosol gene delivery in vivo. Proc Natl Acad Sci USA, 1992, 89:112-77.
46. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A.: Therapeutic effect of a retroviral wild-type p. 53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst, 1994 Oct, 5;86(19):1458-62.
47. Zhang W.W., Fang X., Mazur W., French B.A., Georges R.N., Roth J.A.: High-efficiency gene transfer and high-level expression of wild-type p. 53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther, 1994 Mar, 1(1):5-13.
48. Cai D.W., Mukhopadhyay T, Liu Y., Fujiwara T, Roth J.A.: Stable expression of the wild-type p. 53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther, 1993 Oct, 4(5):617-24.
49. Nishizaki M., Fujiwara T, Tanida T., Hizuta A., Nishimori H, Tokino T., Nakamura Y., Bouvet M., Roth J.A., Tanaka N.: Recombinant adenovirus expressing wild-type p. 53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res, 1999 May, 5(5): 1015-23.
50. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R, Lee J.J., Nesbitt J.C., Pisters K.M., Putnam J.B., Schea R, Shin D.M., Walsh G.L., Dolormente M.M., Han C.I., Martin F.D., Yen N., Xu K, Stephens L.C., McDonnell T.J., Mukhopadhyay T., Cai D.: Retrovirus-mediated wild-type p. 53 gene transfer to tumors of patients with lung cancer. Nat Med, 1996 Sep, 2(9):985-91.
51. Schuler M., Rochiitz C., Horowitz J.A., Schlegel J., Perruchoud P., Kommoss F, Bolliger C.T., Kauczor H.U., Dalquen P., Fritz M.A., Swanson S, Herrmann R, Huber C.: A phase I study of adenovirus-mediated wild-type p. 53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther, 1998 Sep. 20;9(14):2075-82.
52. Swisher S.G., Roth J.A., Nemunaitis J., Lawrence D.D., Kemp L., Carrasco C.H., Connors D.G., El-Naggar A.K., Fosselia F, Glisson B.S., Hong W.K., Khuri F.R., Kurie J.M., Lee J.J., Lee J.S., Mack M., Merritt J.A., Nguyen D.M., Nesbitt J.C., Perez- Soler R., Pisters K.M., Putnam J.B. Jr, Richli W.R., Savin M, Waugh M.K., et al: Adenovirus-mediated p. 53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999 May, 5;91(9):763-71.
53. Kubba S, Adak S, Schiller J .: Phase I trial of adenovirus p. 53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bron- choalveolar lavage. Proc Am Soc Clin Oncol, 2000, 19:487a.
54. Horio Y., Hasegawa Y, Sekido Y, Takahashi M, Roth J.A., Shimokata K.: Synergistic effects of adenovirus expressing wild-type p. 53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther, 2000 Apr, 7(4):537-44.
55. Nishizaki M, Meyn R.E., Levy L.B., Atkinson E.N., White R.A., Roth J.A., Ji L.: Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p. 53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res, 2001 Sep, 7(9):2887-97.
56. Lowe S.W., Ruley H.E., Jacks T, Housman D.E.: p. 53-depen- dent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993 Sep, 24;74(6):957-67.
57. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A.: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild- type p. 53 gene. Cancer Res, 1994 May, 1;54(9):2287-91.
58. Nemunaitis J., Swisher S, Timmons T. et aL.: Adenovirus-mediated p. 53 gene transfer in sequence with cisplatin to tumors of patients with non small cell lung cancer. J Clin One, 2000, 18: 609-22.
59. Schuler M., Herrmann R., De Greve, J.L., Stewart A.K., Gatzemeier U., Stewart D.J., Laufman L., Gralla R., Kuball J., Buhl R., Heussel C.P., Kommoss F., Perruchoud A.P., Shepherd F.A., Fritz M.A., Horowitz J.A., Iluber C., Rochlitz C.: Adenovirus-mediated wild-type p. 53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol, 2001 Mar, 15; 19(6): 1750-8.
60. Swisher S.G., Roth J.A., Komaki R, Gu J., Lee J.J., Hicks M Ro J.Y., Hong W.K., Merritt J.A., Ahrar K Atkinson N.E., Correa A.M., Dolormente M., Dreiling L., El-Naggar A.K., Fossella F., Francisco R., Glisson B., Grammer S., Herbst R., Huaringa A., Kemp B., Khuri F.R., Kurie J.M., Liao Z., McDonnell T.J., Morice R., Morello F., Munden R., Papadimitrakopoulou V., Pisters K.M., Putnam J.B. Jr, Sarabia A.J., Shelton T., Stevens C., Shin D.M., Smythe W.R., Vaporciyan A.A., Walsh G.L., Yin M.: Induction of p. 53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p. 53 (INGN 201) and radiation therapy. Clin Cancer Res, 2003 Jan, 9(1):93-101.
61. Bischoff J.R., Kim D.H., Williams A., Heise C, Horn S, Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F.: An adenovirus mutant that replicates selectively in p. 53-deficient human tumor cells. Science, 1996 Oct, 18;274(5286):373-.
62. Kim D., Henniston T, McCormick F.: ONYX-O15: clinical data are encouraging. Nat Med, 1998 Dec, 4(12): 1341-2.
63. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff, D.D., Kim D.H.: ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med, 1997 Jun, 3(6):639-45.
64. You L, Yang C.T., Jablons D.M.: ONYX-O15 works synergisti- cally with chemotherapy in lung cancer cell lines and primary cultures freshly modi from lung cancer patients. Cancer Res, 2000 Feb, 15;60(4): 1009-13.
65. Nemunaitis J., Cunningham C., Buchanan A., Blackburn A., Edelman G, Maples P., Netto G., Tong A., Randlev B., Olson S., Kirn D.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther, 2001 May, 8(10):746-59.
66. Zamacnik P.: Background of the antisense oligonicleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev, 1997, 7: 199-202.
67. Robinson L.A., Smith U., Fontaine M.P., Kay H.D., Mountjoy C.P., Pirruccello S.J.: c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg, 1995 Dec, 60(6): 1583-91.
68. Mukhopadhyay T., Tainsky M., Cavender A.C., Roth J.A.: Specific inhibition ofK-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res, 1991 Mar, 15:51(6): 1744-8.
69. Roth J.: Modification of mutant k-ras gene expression in non small cell lung cancer (NSCLC). Hum Gen Ther, 1996, 7:875.
70. Deshane J., Siegal G.P., Wang M, Wright M, Bucy R.P., Alvarez R.D., Curiel D.T.: Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy. Gynecol Oncol, 1997 Mar, 64(3):378-85.
71. Cochet O., Kenigsberg M., Delumeau I., Virone-Oddos A., Multon M.C., Fridman W.H., Schweighoffer F., Teillaud J.L., Tocque B.: Intracellular expression of an antibody fragment-neutrali- zing p. 21 ras promotes tumor regression. Cancer Res, 1998 Mar, 15;58(6):1170-6.
72. Deshane J., Siegal G.P., Alvarez R.D., Wang M.I.I., Feng M, Cabrera G., Liu T., Kay M., Curiel D.T.: Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest, 1995 Dec, 96(6):2980-9.
73. Pope I., Poston G., Kinsella A.: The role of the bystander effect in suicide gene therapy. Eur J Cancer, 1997, 33:1005-16.
74. Hwang F.I.C., Smythe W.R., Elshami A.A., Kucharczuk J.C., Amin K.M., Williams J.P., Litzky L.A., Kaiser L.R., Albelda S.M.: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol, 1995 Jul, 13(1):7- 16.
75. Fukunaga M., Takamori S., Hayashi A., Shirouzu K., Kosai K.: Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann Thorac Surg, 2002 Jun, 73(6): 1740-6.
76. Sterman D.I.I., Treat J., Litzky L.A., Amin K.M., Coonrod L., Molnar-Kimber K, Recio A., Knox L, Wilson J.M., Albelda S.M., Kaiser L.R.: Adenovirus-mediated herpes simplex virus thymidine kina-se/ganciclovir gene therapy in patients with localized malignancy: results of a phase 1 clinical trial in malignant mesothelioma. Hum Gene Ther, 1998 May, 1;9(7): 1083-92.
77. Sterman D.H., Molnar-Kimber K., Iyengar T., Chang M, Lanuti M., Amin K.M., Pierce B.K., Kang E., Treat J., Recio A., Litzky L., Wilson J.M., Kaiser L.R., Albelda S.M.A.: Pilot study of systemic corticosteroid administration in coniunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther, 2000 Dec, 7(12):1511-8.
78. Sharma S, Miller P.W., Stolina M., Zhu L, Huang M, Paul R.W., Dubinett S.M.: Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther, 1997 Dec, 4(12):1361-70.
79. Haku. T., Yanagawa H., Nabioullin R., Takeuchi E., Sone S.: Interleukin-I2-mediated killer activity in lung cancer patients. Cytokine, 1997 Nov, 9(2):846-52.
80. Lee C.T., Wu S, Ciemik I.F., Chen H, Nadaf-Rahrov S, Gabrilovich D., Carbone D.P.: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther, 1997 Jan, 20;8(2): 187-93.
81. Robinson B.W., Mukherjee S.A., Davidson A., Morey S., Musk A.W., Ramshaw I., Smith D., Lake R Haenel T., Garlepp M, Marley J., Leong C., Caminschi I., Scott B.: Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother, 1998 May. 21(3):211-7.
82. Escudier B, Le Chavalier T, Angevin F.: Lung Cancer, 2000, 29(Suppl):184(abstract 622).
83. Nemunaitis J., Sterman D., Jablons D. et al: A phase 1/11 study of autologous GMCSF gene modified cancer vaccines in subjects with non small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20:255a, (abs 1019).
84. Folkman J.: Fundamental concepts of the angiogenic process. Curr Mol Med, 2003 Nov, 3(7):643-51.
85. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., Woo S.L.: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA, 2000 Apr. 25;97(9):4802-7.
86. Volm M., Koomagi R., Mattem J.: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer, 1997 Feb, 20;74(1):64-8.
87. Chen Z, Fisher R.J., Riggs C.W., Rhim J.S., Lautenberger J.A.: Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETSI antisense oligonucleotides. Cancer Res, 1997 May, 15;57(10):2013-9.